RxDoctor Payments Data

Fred Thomas, MD

Internal Medicine · Hampton, VANPI 1518958420

Payments from drug & device makers

$4,960in general payments, 2019–2025

Across 292 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$737
  • Novo Nordisk$612
  • GSK$490
  • Boehringer Ingelheim$485
  • AstraZeneca$440
  • Pfizer$392
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,91999%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,960 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$139,803
Medicare patients
225
Services billed
3,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban54$55,174
OzempicSemaglutide48$51,112
TrulicityDulaglutide35$39,047
JanuviaSitagliptin Phosphate44$37,046
JardianceEmpagliflozin27$32,621
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$26,948
EliquisApixaban27$19,361
FarxigaDapagliflozin Propanediol23$13,155
MounjaroTirzepatide11$11,295
EntrestoSacubitril/Valsartan12$9,815
JanumetSitagliptin Phos/Metformin Hcl13$7,318
LinzessLinaclotide13$7,198
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,898
Tacrolimus12$1,741
Atorvastatin Calcium180$1,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$53$55,17454 claims
Novo NordiskOzempic$612$51,11248 claims
Lilly USA, LLCTrulicity, Mounjaro$297$50,34246 claims
MerckJanuvia, Janumet$196$44,36457 claims
Boehringer IngelheimJardiance$485$32,62127 claims
GSKTrelegy Ellipta$490$26,94834 claims
PfizerEliquis$392$19,36127 claims
AstraZenecaFarxiga$440$13,15523 claims
NovartisEntresto$48$9,81512 claims
AbbVieLinzess, Synthroid$737$7,54325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Hampton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →